BJMO - , issue ,
A. de la Taille
Data regarding the natural history of prostate cancer (PCa) disease confirm the clinical insignificance of low-grade prostate cancer, which is associated with scant or no metastatic dissemination. Active surveillance (AS) is a conservative management approach, conducted for patients with “low-” or “favorable-risk” disease, which avoids long-term adverse effects on the patient’s quality of life. In a lecture during BMUC 2018, Prof. de la Taille explained why he thinks that AS is an option that we need to consider and why we should discuss this with the patient before the biopsy is taken.
Read moreBJMO - , issue ,
A. de la Taille
Over the last 10 years we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The introduction of several new therapeutic modalities had a significant impact on the overall survival (OS) of these patients. Whereas the median OS for patients with mCRPC was only 24.2 months back in 1997, this has increased to 39.4 months in a patient cohort from 2007 to 2013. This represents an increase in the median OS with 1.5 years.1 Currently, patients with mCRPC have 6 different drugs at their disposal. The question now is: “how to best sequence these different options?”
Read moreBJMO - volume 12, issue 10, march 2018
A. de la Taille
Data regarding the natural history of prostate cancer (PCa) disease confirm the clinical insignificance of low-grade prostate cancer, which is associated with scant or no metastatic dissemination. Active surveillance (AS) is a conservative management approach, conducted for patients with “low-” or “favorable-risk” disease, which avoids long-term adverse effects on the patient’s quality of life. In a lecture during BMUC 2018, Prof. de la Taille explained why he thinks that AS is an option that we need to consider and why we should discuss this with the patient before the biopsy is taken.
BJMO - volume 12, issue 10, march 2018
A. de la Taille
Over the last 10 years we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The introduction of several new therapeutic modalities had a significant impact on the overall survival (OS) of these patients. Whereas the median OS for patients with mCRPC was only 24.2 months back in 1997, this has increased to 39.4 months in a patient cohort from 2007 to 2013. This represents an increase in the median OS with 1.5 years.1 Currently, patients with mCRPC have 6 different drugs at their disposal. The question now is: “how to best sequence these different options?”
Top
